News

Larazotide acetate, a tight junction modulator, is progressing towards a Phase IIb clinical trial for the treatment of celiac disease. Cephalon will pay Alba a $7m upfront option

RADIANT-3, a prospective, double-blind, randomized, parallel group, placebo-controlled, multicenter study, examined the efficacy and safety of everolimus plus BSC versus placebo plus BSC in 410 patients with advanced,

Orexigen adopted this course of action following the receipt of complete response letter from the US Food and Drug Administration on 31 January 2011 regarding the new drug

The Mucinex products are indicated to loosen phlegm (mucus) and thin bronchial secretions to clear the bronchial passageways of troublesome mucus and make coughs more productive. Reportedly, in

The C-Suite EMR is a SaaS software solution that utilizes the cloud to ensure its ease of use, medical billing and practice management firm CSC said. CSC CEO

The placebo-controlled, double-blind study evaluates the safety, tolerability, and pharmacokinetics of RK-023 in healthy adult male and female volunteers, who will apply the study drug to the eyelid

The studies evaluated the effect of bafetinib on bone cells (osteoclasts) from multiple myeloma patients. The study results showed that in two model systems, bafetinib significantly suppressed the

The agreement requires Lundbeck to register and commercialise key products which are currently available in the US and/or Europe on behalf of Cephalon including Fentora (fentanyl buccal tablet)

The new labels now carry US prescribed information on medication guides, additional safety and restrictions on the use of these medicines for cardiovascular event data in type 2